Marshall Wace
ORGS

Marshall Wace’s Orgenesis Inc. Common Stock ORGS Stock Holding History

Marshall Wace’s Portfolio ORGS Stock Details ORGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,333
Closed -$66K – 4373
2021
Q3 		$66K Sell
1,333
-1,679
-56% -$84.3K ﹤0.01% 2921
2021
Q2 		$153K Buy
+3,012
New +$152K ﹤0.01% 2493

Other funds holding ORGS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RC
Ronit Capital London, United Kingdom $74.3M AUM 13.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BHB
Bank Hapoalim BM Tel Aviv, Israel $1.5B AUM 26.39% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Marshall Wace's ORGS Position: Q4 2021 in Review

Marshall Wace sold out of Orgenesis Inc. Common Stock (ORGS) in Q4 2021, closing a stake of 1,333 shares — an estimated $66K sold.

Marshall Wace first reported a position in ORGS in Q2 2021 and held it in 2 quarters. The position peaked at $153K in Q2 2021. 26 funds tracked by Wall St. Rank hold ORGS as of Q4 2021.

  • Marshall Wace reported no remaining Orgenesis Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Marshall Wace sold 1,333 Orgenesis Inc. Common Stock shares in Q4 2021, an estimated $66K.
  • Marshall Wace first reported a position in Orgenesis Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Marshall Wace's Orgenesis Inc. Common Stock position peaked at $153K in Q2 2021.
  • 26 funds tracked by Wall St. Rank held Orgenesis Inc. Common Stock as of Q4 2021.

Based on Marshall Wace's 13F filing for Q4 2021, filed 14 Feb 2022.